65,437 trials
Moderate-to-Severe Atopic Dermatitis · Dermatitis, Dermatitis Atopic · Eczema, Skin Diseases, Skin
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction From Baseline of ≥2 Points) at Week 16 — 2.4; 17.9; 24.4 Percentage of…
Plaque · Gingivitis
Primary: Within-Treatment Whole-Mouth Differences (vs Baseline) - Gingival Efficacy — .230; .155; .3701; .205 units on a scale
Extensive Stage Small Cell Lung Carcinoma
Primary: Progression Free Survival (PFS) — 5.88; 5.85 Months — p=0.8072
Presbycusis · Aging · Hearing Loss
Primary: Profile of Hearing Aid Performance Benefit (PHAB) — 0.17; 0.12; 0.04 Proportion of time had difficulties
Solid Tumor
Primary: Percentage of Participants With Serious Adverse Events Considered Related to Onartuzumab — 0 Percent
Smoking Cessation
Primary: 7-day Point Prevalence of Smoking Abstinence — 8; 11; 25; 20 Participants — p=0.3253
Contraception
Primary: Number of Pregnancies (Evaluable Cycles) — 2.9 Pearl Index
Glabellar Furrows
Primary: Reduction of the Facial Wrinkle Scale — 1.86; 2.10 units on a scale — p=<.001
Bone Diseases, Metabolic
Primary: Change From Baseline in Silicon Absorption at 12 Weeks — 0.010; 0.016; 0.009; 0.037 mg/mg creatinine — p=0.003
Endometriosis
Primary: Change From Baseline in Individual Biberoglu Behrman Symptom Severity Scale (BBSS) Score for Dysmenorrhea — 12.6; 10.8; 11.1; -3.95 score on a scale per 28-day period…
Solid Tumor
Primary: Patients With Elevated Par-4 Levels — 3; 2; 1 Participants
Asthma
Primary: Baseline-adjusted FEV1 30 Minutes After Each Cumulative Dose — 0.421; 0.488; 0.548; 0.586 Liter
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Overall Response Rate (ORR) — 13.0; 4.3 Percentage of participants
Hypoxia
Primary: It Was Expected That the Accuracy Root Mean Square (ARMS) Between Measured SpO2 of Owlet Smart Sock V2 v1.1 and Reference SpO2 Would Meet the Required Specification of…
End-Stage Renal Disease
Primary: Safety - Number of Participants With Serum Potassium >6.5 mEq/L — 9; 4; 4; 8 Participants